topics / investigational
Tagged investigational.
- Preliminary human Amycretin An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere.
- Preliminary human ARA-290 (Cibinetide): A Non-Blood-Building EPO Fragment With Early, Conflicted Human Data ARA-290 is an investigational EPO-derived peptide studied for nerve injury. Real but small, short, developer-run trials exist — no Phase 3 and no approval.
- Preliminary human Cagrilintide: A Long-Acting Amylin Analog with Strong Combination Data and Thin Standalone Evidence Cagrilintide is an investigational once-weekly amylin analog from Novo Nordisk. The robust human data are for the CagriSema combination, not the drug alone.
- Strong human CagriSema An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide.
- Preliminary human Ecnoglutide A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved.
- Preliminary human Kisspeptin-10: A Real Hormone Switch With Thin Human Evidence Kisspeptin-10 reliably raises reproductive hormones in short human studies, but the headline fertility and libido results belong to a different molecule, kisspeptin-54.
- Preliminary human Mazdutide: real Phase 3 data, but almost all of it from China A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country.
- Preliminary human MK-677 (Ibutamoren): A Lot of Human Data, Little to Show for It MK-677 reliably raises growth hormone and IGF-1, but disease trials failed and one was stopped for a heart-failure signal. Investigational, never approved.
- Preliminary human Ostarine (MK-2866) Ostarine is an investigational selective androgen receptor modulator (SARM) — not a peptide — with real but limited human evidence for lean-mass effects, no regulatory approval anywhere, and documented liver-injury and hormone-suppression signals.
- Animal only Testolone (RAD-140) An investigational, non-approved selective androgen receptor modulator (SARM) with no published human efficacy evidence for fitness use, a documented serious liver-injury case, and prohibited status in sport.
- Preliminary human Retatrutide An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results.
- Preliminary human Survodutide: Strong Phase 2 data and a first Phase 3 readout, but still investigational An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data.
- Preliminary human VK2735 (Viking) VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown.